Pennsylvania is currently home to 3466 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Recruiting
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Dermdox Center For Dermatology, Sugarloaf, Pennsylvania
Conditions: Atopic Dermatitis
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Recruiting
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Dermatology Associates of Plymouth Meeting, Plymouth Meeting, Pennsylvania
Conditions: NonSegmental Vitiligo
Managing Chronic Tendon Pain by Metformin
Recruiting
The purpose of the current exploratory clinical trial is to determine the effect of oral ingestion of metformin (OIM) in non-diabetic patients with chronic Achilles tendon pain. The trial has two aims; 1) to assess the effects of OIM treatment on tendon pain, and 2) to determine the effects of OIM capsules on tendon healing and repair. Twenty participants will be treated with metformin capsules for 16 weeks combined with a home exercise program. A comparison group of 20 participants will be trea... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
05/02/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Tendinopathy, Chronic Pain, Achilles Tendinopathy
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Recruiting
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Gender:
All
Ages:
Between 12 years and 130 years
Trial Updated:
05/02/2024
Locations: Research Site, Pittsburgh, Pennsylvania
Conditions: Hypophosphatasia
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Recruiting
This is a medical research study to test a medication in patients 10 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and efficac... Read More
Gender:
All
Ages:
10 years and above
Trial Updated:
05/02/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Recruiting
This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with MCADD.
Gender:
All
Ages:
16 years and above
Trial Updated:
05/02/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Helix Research Network
Recruiting
The Helix Research Network ("HRN") is a network of academic, public, and/or private healthcare organizations that are committed to advancing medical research and improving human health through large-scale genomics research and acceleration of the integration of genomic and other omics data into clinical care.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: St. Luke's University Health Network (DNAanswers), Bethlehem, Pennsylvania
Conditions: Genetic Predisposition to Disease, Genetics Disease
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Recruiting
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer sur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Recruiting
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer, Cancer, Lung
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Recruiting
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
05/02/2024
Locations: The University of Pennsylvania - Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Multiple System Atrophy (MSA)